EQS-Adhoc: BB Biotech AG closes the 2024 fiscal year with a profit
|
EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Annual Results Ad hoc announcement pursuant to Art. 53 LR January 24, 2025 BB Biotech AG closes the 2024 fiscal year with a profit In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information: Based on its preliminary unaudited consolidated figures, BB Biotech AG reports a profit of approximately CHF 76 million for the financial year 2024 (loss of CHF 207 million in the previous year). For an investment company, the results reflect the share price development of the companies held in the portfolio. The publication of all relevant portfolio data will take place on January 24, 2025 at 7:00am and the complete annual report will be published on February 21, 2025.
Media Relations Company profile End of Inside Information
24-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | BB BIOTECH AG |
| Schwertstrasse 6 | |
| 8200 Schaffhausen | |
| Switzerland | |
| Phone: | +41 52 624 08 45 |
| E-mail: | info@bbbiotech.com |
| Internet: | www.bbbiotech.ch |
| ISIN: | CH0038389992 |
| WKN: | A0NFN3 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Mailand, SIX |
| EQS News ID: | 2073701 |
| End of Announcement | EQS News Service |
|
|
2073701 24-Jan-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 669,48 | 683,90 | 0,00 | 1,28 | 0,57 | 119,28 | 0,00 | |
| EBITDA1,2 | 624,04 | 637,31 | -390,46 | -361,02 | -222,29 | 86,01 | 0,00 | |
| EBITDA-Margin3 | 93,21 | 93,19 | 0,00 | -28.204,69 | -38.998,25 | 72,11 | 0,00 | |
| EBIT1,4 | 624,04 | 637,31 | -390,46 | -361,02 | -222,29 | 86,01 | 0,00 | |
| EBIT-Margin5 | 93,21 | 93,19 | 0,00 | -28.204,69 | -38.998,25 | 72,11 | 0,00 | |
| Net Profit (Loss)1 | 622,84 | 637,24 | -390,53 | -362,83 | -222,41 | 80,66 | 0,00 | |
| Net-Margin6 | 93,03 | 93,18 | 0,00 | -28.346,09 | -39.019,30 | 67,62 | 0,00 | |
| Cashflow1,7 | 197,69 | 241,97 | -91,44 | 234,37 | 234,97 | 323,67 | 0,00 | |
| Earnings per share8 | 11,24 | 11,51 | -7,05 | -6,59 | -4,05 | 1,47 | 1,70 | |
| Dividend per share8 | 3,20 | 3,32 | 3,67 | 2,88 | 2,10 | 1,91 | 1,95 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Deloitte
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| BB Biotech | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0NFN3 | CH0038389992 | AG | 1.623,22 Mio € | 10.12.1997 | Kaufen | 8FVCMJWM+W3 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 15,42 | 11,85 | 1,30 | -132,58 | 0,70 | 5,01 | 13,61 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 2,88 | 2,10 | 1,91 | 6,52% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 19.03.2025 | 25.04.2025 | 25.07.2025 | 24.10.2025 | 21.02.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -23,59% | -26,47% | -21,34% | -33,18% | +516,84% |
